Shilpa Medicare Launches NODUCA™, a First-in-Class Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease in India
Shilpa Medicare Ltd. has announced the launch of NODUCA™ (Nor Ursodeoxycholic Acid (NorUDCA)), a first-in-class therapy for metabolic dysfunction-associated fatty liver disease (MAFLD) in India. This landmark approval designates Shilpa Medicare as the first company globally to bring Nor Ursodeoxycholic tablets to market for the treatment of MAFLD. NorUDCA represents a novel, first-in-class therapy demonstrating significant clinical efficacy and safety in reversing liver fibrosis and stabilizing liver function. Shilpa Medicare Limited is now commencing commercial launch within India under its own brand NODUCA™ and have also partnered with 3 partners for the India market on their own brand. The company is also pursuing international regulatory approvals to expand access to this vital liver health therapy for patients globally.
Key Highlights
- Shilpa Medicare launches NODUCA™, a first-in-class therapy for metabolic dysfunction-associated fatty liver disease (MAFLD) in India.
- NODUCA™ is a novel, first-in-class therapy demonstrating significant clinical efficacy and safety in reversing liver fibrosis and stabilizing liver function.
- Shilpa Medicare is the first company globally to bring Nor Ursodeoxycholic tablets to market for the treatment of MAFLD.
- Shilpa Medicare is now commencing commercial launch within India under its own brand NODUCA™ and have also partnered with 3 partners for the India market on their own brand.
- Shilpa Medicare is pursuing international regulatory approvals to expand access to this vital liver health therapy for patients globally.